• Explore /
  • Poster
  • / Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial.

Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial.

Abstract Poster

Authors

null

Oleg Gluz

West German Study Group, Moenchengladbach, Germany

Oleg Gluz , Cornelia Liedtke , Aleix Prat , Matthias Christgen , Daniel Gebauer , Ronald E. Kates , Eva-Maria Grischke , Helmut Forstbauer , Michael Wilhelm Braun , Mathias Warm , John Hackmann , Christoph Uleer , Bahriye Aktas , Claudia Schumacher , Sherko Kummel , Rachel Wuerstlein , Enrico Pelz , Ulrike Nitz , Hans Heinrich Kreipe , Nadia Harbeck

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT01815242

Citation

J Clin Oncol 35, 2017 (suppl; abstr 573)

DOI

10.1200/JCO.2017.35.15_suppl.573

Abstract #

573

Poster Bd #

173

Abstract Disclosures

Similar Posters

First Author: Oleg Gluz

First Author: Lisa Katharina Katharina Richters

First Author: Matt D. Galsky

First Author: Gaia Griguolo